Home | Site Map | About | Contact 
  The scientific approach to weight loss and maintenance. Indepenent, hype-free research.
 
Weight Loss Guide
 Weight Loss Basics
 Diets & Dieting
 Drug Therapy
 Supplements
 Weight Loss Surgery
 Tools & Calculators
 
News & Research
 Weight Loss News
 Published Studies
   > Drugs
   > Diets
   > Supplements
   > Surgery
   > Lifestyle
 Clinical Trials
 
 
 
 
 
 
 
   
You are here: Published Weight Loss Studies >

Anesthetic considerations for the new antiobesity medications.

Author: Jeffers LA

Author affiliation: Mt. Sinai School of Nurse Anesthesia, Cleveland, Ohio, USA.

Publication date & source: 1996.12, AANA J., 64(6):541-4.

Publication type: Review

Combination drug therapy can effectively treat the problem of obesity. The most commonly used combination is a mix of fenfluramine and phentermine. Fenfluramine inhibits the reuptake of serotonin and acts on the hypothalmic appetite control center, while phentermine acts as an appetite suppressant. These drugs along with diet and exercise effectively help people to lose weight with few side effects. However, there are several anesthetic considerations when providing anesthesia services for patients on the fenfluramine and phentermine regimen. Problems of hypotension on induction, hypoglycemia, hyperthermia, and pulmonary hypertension have been reported in the literature. Recently, dexfenfluramine (Redux) was approved by the U.S. Food and Drug Administration. It is the dextrostereoisomer of fenfluramine and is believed to produce the same weight loss with less side effects. Anesthesia providers must understand the potential risks involved when administering a general anesthetic to these patients.



Indexes of Weight Loss Research Abstracts
Weight Loss Drugs
Weight Loss Diets
Supplements
Bariatric Surgery
Lifestyle


Back to Published Weight Loss Studies

     
-- advertisements --


Copyright © 2006 by Weight-Loss-Science.com
All inormation is for education purposes only and should not be considered as a medical advice.